Precision for Medicine, part of Precision Medicine Group, has just expanded its global reach through the acquisition of Argint International, a contract research organization based in Budapest, Hungary. The acquisition is part of Precision’s global growth plan; Precision’s European footprint now includes offices in Edinburgh, Paris, Berlin, Geneva, Budapest, Bucharest, Bratislava, and Belgrade.
Precision’s expanded workforce, expertise, and locations will provide direct support and greater geographic reach for its global oncology, rare disease, and cardiovascular clinical trial operations, as well as increased presence and access to investigators and patients throughout the central and southeastern European regions.
Precision’s full-time staff throughout Europe has now grown to more than 300 employees, allowing the company to fully support pharmaceutical and life sciences innovators in all facets of the business, including specialty lab services, biomarker informatics, clinical trial solutions, diagnostics and medical device services, and biomaterials.
Commenting on Precision for Medicine’s growth, President Chad Clark remarked, “Argint International is an ideal fit with Precision for Medicine. Their commitment to quality and client service, proven over more than a decade of delivering for leading biotechnology companies, is perfectly aligned with Precision’s vision and culture. The addition of the Argint team augments and enhances our European platform, which is critical due to the significant number of customers we have throughout Europe—and also the number of sites and patients seeking novel therapies derived from the benefits of precision medicine.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are thrilled to be joining the Precision for Medicine family,” said Agnes Pinnel, CEO of Argint International. “As part of Precision we join an organization that shares our values, expands our capabilities, and offers growth potential for our people. In particular, we are excited to join with a leader in biomarker-based precision medicine programs, one of the fastest growing and important parts of drug development.”
Fairmount Partners, a leading investment bank worldwide for pharmaceutical, device, and related service businesses, acted as exclusive financial advisor to Argint.
Date: October 1, 2018
Source: Pharmiweb